Switching Crohn’s disease patients from Remicade (infliximab) to its biosimilar Inflectra has no negative impact to treatment safety or effectiveness, a Phase 3 clinical trial shows. Pfizer and Celltrion Healthcare jointly presented ... Read more
TiGenix has started a pivotal Phase 3 clinical trial of Cx601’s ability to treat a complication of Crohn’s disease known as complex perianal fistulas. Fistulas are sores between the end of the ... Read more
RedHill Biopharma Ltd. An Israeli biopharmaceutical company announced that an independent Data and Safety Monitoring Board (DSMB) recommended their MAP US study to continue as planned without any modifications.
Galapagos, a clinical-stage biotech specializing in small molecule medicines, has dosed its first patient in its DIVERSITY (NCT02914561) Phase 3 clinical trial of filgotinib in Crohn’s disease. The trial ... Read more
Pfizer has just announced top-line results from OCTAVE Sustain, the third Phase 3 study investigating Xeljanz (tofacitinib citrate) in patients with moderate-to-severe active ulcerative colitis (UC). The OCTAVE Clinical ... Read more
Researchers in a new study analyzed the outcomes of a clinical trial comparing standard therapy with hematopoietic (blood) stem cell transplantation (HSCT) in Crohn’s disease patients and found that HSCT did ... Read more
Biopharmaceutical company Soligenix, Inc. recently announced in a news release that the U.S. Food and Drug Administration (FDA) has authorized a pivotal Phase 3 clinical trial to assess the ... Read more
Pin It on Pinterest